Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Nanodomain Engineering using a X-omics blueprint of the NK cell Surface

Obiettivo

Natural killer (NK) cells hold enormous promise for cancer therapy, which is explored in nearly 400 clinical trials. Yet, on average only about 40% of patients respond to treatment and it remains difficult to predict why. This challenge stems from a fundamental unknown: how do NK cells decide whether to kill a tumor cell? Traditional models assume this decision is governed by a simple balance of activating and inhibitory receptors, but mounting evidence suggests a more intricate mechanism: the nanoscale spatial organization of these receptors appears to encode specific instructions that determine NK cell behavior. I project that a proximity labeling platform I recently developed represents a key foundation to decipher this code.

In my ERC project called NEXUS I will:
1) Apply a new cutting-edge nanoscale proteomics approach to systematically chart the nanoscale distribution of key NK receptors and their coregulators on the membrane of cultured and primary human NK cells across various activating and repressive conditions.
2) Develop a new spatial interaction proteomics approach to define which receptor-ligand interactions guide NK recognition of tumor targets.
3) Engineer NK cells with optogenetically tunable receptor clustering to causally test how specific receptor organizations govern NK cell activation, immune synapse formation, and target killing.

Together, NEXUS will redefine our understanding of NK cell biology and establish a generalizable framework for how immune cells interpret complex signals through spatial organization. This could open an entirely new dimension of immune regulation and reshape the way we think about immune decision-making, and move immunotherapy design beyond trial-and-error towards new rational, spatially informed NK-cell therapies with transformative potential for cancer treatment.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-STG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Contributo netto dell'UE
€ 1 500 000,00
Indirizzo
GEERT GROOTEPLEIN 10 ZUID
6525 GA Nijmegen
Paesi Bassi
Regione
Oost-Nederland Gelderland Arnhem/Nijmegen
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 500 000,00

Beneficiari (1)